Envestnet Portfolio Solutions Inc. Has $2.30 Million Holdings in Novo Nordisk A/S $NVO

Envestnet Portfolio Solutions Inc. decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 18.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,485 shares of the company’s stock after selling 9,385 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Novo Nordisk A/S were worth $2,302,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Vantage Investment Partners LLC boosted its holdings in Novo Nordisk A/S by 17.5% in the 3rd quarter. Vantage Investment Partners LLC now owns 533,565 shares of the company’s stock valued at $29,608,000 after purchasing an additional 79,441 shares during the period. Northstar Asset Management Inc. raised its position in shares of Novo Nordisk A/S by 31.1% during the third quarter. Northstar Asset Management Inc. now owns 222,348 shares of the company’s stock valued at $12,338,000 after buying an additional 52,791 shares during the last quarter. AAFMAA Wealth Management & Trust LLC lifted its stake in shares of Novo Nordisk A/S by 1.3% in the third quarter. AAFMAA Wealth Management & Trust LLC now owns 15,130 shares of the company’s stock valued at $840,000 after buying an additional 201 shares during the period. Parkside Financial Bank & Trust grew its position in Novo Nordisk A/S by 18.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,405 shares of the company’s stock worth $189,000 after buying an additional 538 shares in the last quarter. Finally, Hara Capital LLC bought a new position in Novo Nordisk A/S during the third quarter valued at about $2,576,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $63.96 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The business’s fifty day moving average price is $52.44 and its two-hundred day moving average price is $54.54. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The stock has a market capitalization of $285.58 billion, a price-to-earnings ratio of 18.59 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 price target on the stock. BMO Capital Markets set a $57.00 price objective on shares of Novo Nordisk A/S in a research note on Monday. Finally, Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $57.79.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.